MX9705572A - Complejos estables para el suministro de farmacos que contienen lipidos y metodos para su produccion. - Google Patents

Complejos estables para el suministro de farmacos que contienen lipidos y metodos para su produccion.

Info

Publication number
MX9705572A
MX9705572A MX9705572A MX9705572A MX9705572A MX 9705572 A MX9705572 A MX 9705572A MX 9705572 A MX9705572 A MX 9705572A MX 9705572 A MX9705572 A MX 9705572A MX 9705572 A MX9705572 A MX 9705572A
Authority
MX
Mexico
Prior art keywords
drug delivery
production
complexes
methods
lipid
Prior art date
Application number
MX9705572A
Other languages
English (en)
Other versions
MXPA97005572A (es
Inventor
Xiang Gao
Leaf Huang
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Publication of MX9705572A publication Critical patent/MX9705572A/es
Publication of MXPA97005572A publication Critical patent/MXPA97005572A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen novedosos complejos estables para la entrega de drogas, concentrados, biologicamente activos, listos para ser utilizados y que contienen lípidos, métodos para su utilizacion. La actividad biologica de los complejos producidos, es comparable a la de las formulaciones preparadas de acuerdo con el método del arte anterior basado en el mezclado conjunto; y, al ser purificados, los complejos producidos mediante el método de la presente invencion, tienen una concentracion de 50 a 500 veces la de los componentes de los complejos formados mediante el mezclado conjunto. El método descrito en la presente, permite la produccion en gran escala de sistemas entregadores de drogas y que contienen lípidos, utiles para la terapia basada en los genes, y para otras aplicaciones.
MXPA/A/1997/005572A 1995-01-23 1997-07-23 Complejos estables para el suministro de farmacosque contienen lipidos y metodos para su produccion MXPA97005572A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/376,701 US5795587A (en) 1995-01-23 1995-01-23 Stable lipid-comprising drug delivery complexes and methods for their production
US08376701 1995-01-23

Publications (2)

Publication Number Publication Date
MX9705572A true MX9705572A (es) 1998-06-28
MXPA97005572A MXPA97005572A (es) 1998-10-30

Family

ID=

Also Published As

Publication number Publication date
US20100184953A1 (en) 2010-07-22
US7655468B2 (en) 2010-02-02
US20130281382A1 (en) 2013-10-24
US8771728B2 (en) 2014-07-08
PT814777E (pt) 2003-03-31
DK0814777T3 (da) 2003-03-03
US20080153166A1 (en) 2008-06-26
ATE227563T1 (de) 2002-11-15
JP4074338B2 (ja) 2008-04-09
AU4703796A (en) 1996-08-14
DE69624801T2 (de) 2003-04-10
IL116856A0 (en) 1996-07-23
CA2211118A1 (en) 1996-08-01
DE69624801D1 (de) 2002-12-19
JPH10512882A (ja) 1998-12-08
ES2186769T3 (es) 2003-05-16
AU709773B2 (en) 1999-09-09
CA2211118C (en) 2009-06-30
EP0814777B1 (en) 2002-11-13
WO1996022765A1 (en) 1996-08-01
US7993672B2 (en) 2011-08-09
US20120178702A1 (en) 2012-07-12
US5795587A (en) 1998-08-18
EP0814777A1 (en) 1998-01-07
ZA96503B (en) 1996-08-07
CN1177291A (zh) 1998-03-25

Similar Documents

Publication Publication Date Title
IL116856A0 (en) Stable-lipid- comprising drug delivery complexes and methods for their production
HU9200823D0 (en) Process for the production of cyclical carbamide derivatives and medical preparations containing them as active agents
AU7576896A (en) Lipopolyamines as transfection agents and their pharmaceutical applications
ES2058411T3 (es) Sustancia fr 901228 y su preparacion.
AU6701890A (en) Process for the production of biologically active protein
UA43348C2 (uk) Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад
HUT76511A (en) Benzoyl derivatives, preparation and use thereot
TW225532B (es)
EP0657534A4 (en) ANTIALLERGIC AGENT.
MY102918A (en) Purified antineoplaston fractions and methods of treating neoplastic disease.
MY115211A (en) Novel amino acid derivatives, their preparation and use
ES2002053A6 (es) Procedimiento para la obtencion de peptidos inihiobidores de renina que contienen grupos hidroxi.
IL131855A0 (en) Aminosulfonylureas with herbicidal activity
ES8403157A1 (es) Un metodo de preparar sustancias biologicamente activas que tienen actividad anti-tumoral.
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
DK0952853T3 (da) Konjugat omfattende et aktivt middel, et polypeptid og en polyether
AR002272A1 (es) Uso de amidas de fenilciclohexilcarboxilicos
DK347788D0 (da) Teicoplaninlignende forbindelser, fremgangsmaade og mikroorganisme til fremstilling deraf og farmaceutisk praeparat indeholdende saadanne forbindelser
ATE25708T1 (de) Biologisch aktive konjugate, ihre herstellung und ihre anwendung.
CA2072797A1 (en) Use of tri (n-butyl) phosphate at low ph in solutions of biologically active proteins for enhanced virucidal activity
MD970230A (en) Diamine ether diclavulanate and process for preparation thereof
HUP0202974A2 (hu) Fémtartalmú ribonukleotid-polipeptidek
AU625831B2 (en) Solubilization of t-pa
AU578125B2 (en) Pyrazine diazohydroxide compounds
EP0332999A3 (en) Peptides with inhibitory activity of enzymatic systems, process for their preparation and pharmaceutical compositions containing them